Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, headquartered in the United States, is a pioneering leader in the biotechnology industry, specialising in immune-driven medicine. Founded in 2009, the company has made significant strides in harnessing the power of the adaptive immune system to develop innovative diagnostic and therapeutic solutions. With a focus on areas such as oncology and infectious diseases, Adaptive Biotechnologies offers unique products like the clonoSEQ® assay, which provides precise insights into the immune repertoire. This technology stands out for its ability to detect and quantify specific immune cells, enabling personalised treatment strategies. Recognised for its contributions to precision medicine, Adaptive Biotechnologies has established a strong market position, collaborating with major pharmaceutical companies and research institutions to advance the field of immunology.
DitchCarbon Score
How does Adaptive Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adaptive Biotechnologies's score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adaptive Biotechnologies's reported carbon emissions
Adaptive Biotechnologies, headquartered in the United States, currently does not have publicly available carbon emissions data for the most recent year. However, the company is committed to addressing climate change through various initiatives. As part of its sustainability efforts, Adaptive Biotechnologies has made a near-term commitment to reduce its carbon footprint, although specific reduction targets have not been disclosed. The company is actively engaged in the Science Based Targets initiative (SBTi), indicating a commitment to align its emissions reduction strategies with climate science. While no absolute emissions figures are available, Adaptive Biotechnologies operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly focusing on sustainability and carbon neutrality. The company’s commitment to climate action reflects a growing trend in the industry towards responsible environmental stewardship. In summary, while specific emissions data is lacking, Adaptive Biotechnologies is taking steps to address its climate impact through commitments to future reductions and participation in industry initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adaptive Biotechnologies is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
